Domain-based biosensor assay to screen for epidermal growth factor receptor modulators in live cells

Assay and Drug Development Technologies

Volumn 10, Issue 1, 2012, Pages 24-36

  Antczak, Christophe ^a   Bermingham, Alun ^a   Calder, Paul ^a   Malkov, Dmitry ^b   Song, Keming ^b   Fetter, John ^b   Djaballah, Hakim ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Sigma Aldrich Co   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2,4 THIAZOLIDINEDIONE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADAPHOSTIN; ALPHA [AMINO(4 AMINOPHENYLTHIO)METHYLENE] 2 (TRIFLUOROMETHYL)PHENYLACETONITRILE; APIGENIN; CALYCULIN A; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBSTATIN; GEFITINIB; GREEN FLUORESCENT PROTEIN; IMATINIB; LAVENDUSTIN A; LYCORINE; MEPACRINE; MIDOSTAURIN; PD 16916; PROTEIN SH2; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VATALANIB; WORTMANNIN;

ARTICLE; BIOSENSOR; CELL ASSAY; CONTROLLED STUDY; DRUG SCREENING; GENE SILENCING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PROTEIN FUNCTION; RNA INTERFERENCE; SCREENING;

ANTINEOPLASTIC AGENTS; BIOSENSING TECHNIQUES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PILOT PROJECTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING;

EID: 84857748374     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2011.423     Document Type: Article

References (46)

1. Gschwind A, Fischer OM, Ullrich A: The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer 2004;4:361-370. (Pubitemid 38579482)
2. Pao W, Chmielecki J: Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010;10:760-774.
3. Hynes NE, Lane HA: ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-354. (Pubitemid 40637826)
4. Ciaccio MF, Wagner JP, Chuu CP, Lauffenburger DA, Jones RB: Systems analysis of EGF receptor signaling dynamics with microwestern arrays. Nat Methods 2010;7:148-155.
5. Botvinnik A, Wichert SP, Fischer TM, Rossner MJ: Integrated analysis of receptor activation and downstream signaling with EXTassays. Nat Methods 2010;7:74-80.
6. Sevecka M, MacBeath G: State-based discovery: A multidimensional screen for small-molecule modulators of EGF signaling. Nat Methods 2006;3:825-831. (Pubitemid 44445830)
7. Grecco HE, Roda-Navarro P, Girod A, et al.: In situ analysis of tyrosine phosphorylation networks by FLIM on cell arrays. Nat Methods 2010;7:467-472.
8. Olive DM: Quantitative methods for the analysis of protein phosphorylation in drug development. Expert Rev Proteomics 2004;1:327-341.
9. Pennucci J, Swanson S, Kaliyaperumal A, Gupta S: Multiplexed evaluation of a cell-based assay for the detection of antidrug neutralizing antibodies to panitumumab in human serum using automated fluorescent microscopy. J Biomol Screen 2010;15:644-652.
10. Ghosh RN, Grove L, Lapets O: A quantitative cell-based high-content screening assay for the epidermal growth factor receptor-specific activation of mitogenactivated protein kinase. Assay Drug Dev Technol 2004;2:473-481. (Pubitemid 39619090)
11. Sigma-Aldrich: EGFR biosensor cell line. www.sigmaaldrich.com/life- science/cells-and-cell-based-assays/egfr-biosensor-cell-line.html (accessed October 25, 2011).
12. Ambion: Silencer select negative control #1. www.ambion.com/catalog/ CatNum.php?4390843 (accessed October 26, 2011).
13. Ramirez CN, Ozawa T, Takagi T, et al.: Validation of a high-content screening assay using whole-well imaging of transformed phenotypes. Assay Drug Dev Technol 2011;9:247-261.
14. Takagi T, Shum D, Parisi M, et al.: Comparison of luminescence ADP production assay and radiometric scintillation proximity assay for Cdc7 kinase. Comb Chem High Throughput Screen 2011;14:669-687.
15. Moyer JD, Barbacci EG, Iwata KK, et al.: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57:4838-4848. (Pubitemid 27468992)
16. Umezawa K, Hori T, Tajima H, et al.: Inhibition of epidermal growth factorinduced DNA synthesis by tyrosine kinase inhibitors. FEBS Lett 1990;260:198-200. (Pubitemid 20042366)
17. Onoda T, Iinuma H, Sasaki Y, et al.: Isolation of a novel tyrosine kinase inhibitor, lavendustin A, fromStreptomyces griseolavendus. J Nat Prod 1989;52:1252-1257. (Pubitemid 20101774)
18. Blencke S, Ullrich A, Daub H: Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem 2003;278:15435-15440. (Pubitemid 36799884)
19. Wakeling AE, Guy SP, Woodburn JR, et al.: ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-5754. (Pubitemid 35204731)
20. Fry DW, Kraker AJ, McMichael A, et al.: A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994;265:1093-1095. (Pubitemid 24293076)
21. Hsu CY, Jacoski MV, Maguire MP, Spada AP, Zilberstein A: Inhibition kinetics and selectivity of the tyrosine kinase inhibitor erbstatin and a pyridone-based analogue. Biochem Pharmacol 1992;43:2471-2477.
22. Hsu CY, Persons PE, Spada AP, et al.: Kinetic analysis of the inhibition of the epidermal growth factor receptor tyrosine kinase by Lavendustin-A and its analogue. J Biol Chem 1991;266:21105-21112. (Pubitemid 21908580)
23. Patyna S, Laird AD, Mendel DB, et al.: SU14813: A novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 2006;5:1774-1782. (Pubitemid 44323245)
24. Ciardiello F, Caputo R, Bianco R, et al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-2063. (Pubitemid 30305105)
25. Druker BJ, Tamura S, Buchdunger E, et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566.
26. Wood JM, Bold G, Buchdunger E, et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-2189. (Pubitemid 30225181)
27. Dolle RE, Dunn JA, Bobko M, et al.: 5,7-Dimethoxy-3-(4-pyridinyl) quinoline is a potent and selective inhibitor of human vascular beta-type plateletderived growth factor receptor tyrosine kinase. J Med Chem 1994;37:2627-2629. (Pubitemid 24273454)
28. Zaman GJ, Vink PM, van den Doelen AA, Veeneman GH, Theunissen HJ: Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor beta-receptor (beta-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases. Biochem Pharmacol 1999;57:57-64. (Pubitemid 29012496)
29. Martiny-Baron G, Kazanietz MG, Mischak H, et al.: Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J Biol Chem 1993;268:9194-9197. (Pubitemid 23145960)
30. Fabbro D, Ruetz S, Bodis S, et al.: PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000;15:17-28. (Pubitemid 30364896)
31. Sato F, Matsukawa Y, Matsumoto K, Nishino H, Sakai T: Apigenin induces morphological differentiation and G2-M arrest in rat neuronal cells. Biochem Biophys Res Commun 1994;204:578-584. (Pubitemid 24343959)
32. Atkins CM, Selcher JC, Petraitis JJ, Trzaskos JM, Sweatt JD: The MAPK cascade is required for mammalian associative learning. Nat Neurosci 1998;1:602-609.
33. Hancock CN, Macias A, Lee EK, et al.: Identification of novel extracellular signalregulated kinase docking domain inhibitors. J Med Chem 2005;48:4586-4595. (Pubitemid 40993419)
34. Gallagher TF, Seibel GL, Kassis S, et al.: Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg Med Chem 1997;5:49-64. (Pubitemid 27065349)
35. Wu C, Wangpaichitr M, Feun L, et al.: Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 2005;4:25.
36. Shearman MS, Beher D, Clarke EE, et al.: L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry 2000;39:8698-8704. (Pubitemid 30602778)
37. Yoshimoto A, Matsuzawa Y, Oki T, et al.: Microbial conversion of epsilonpyrromycinone and epsilon-isorhodomycinone to 1-hydroxy-13- dihydrodaunomcyin and N-formyl-1-hydroxy-13-dihydrodaunomycin and their bioactivities. J Antibiot (Tokyo) 1980;33:1150-1157. (Pubitemid 11201998)
38. Tassaneeyakul W, Birkett DJ, Veronese ME, et al.: Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 1993;265:401-407. (Pubitemid 23320988)
39. Svingen PA, Tefferi A, Kottke TJ, et al.: Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin Cancer Res 2000;6:237-249. (Pubitemid 30064999)
40. Fan HT, Morishima S, Kida H, Okada Y: Phloretin differentially inhibits volumesensitive and cyclic AMP-activated, but not Ca-activated, Cl(-) channels. Br J Pharmacol 2001;133:1096-1106. (Pubitemid 32762421)
41. Lombardo LJ, Lee FY, Chen P, et al.: Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-6661. (Pubitemid 40053752)
42. Ishihara H, Martin BL, Brautigan DL, et al.: Calyculin A and okadaic acid: Inhibitors of protein phosphatase activity. Biochem Biophys Res Commun 1989;159:871-877. (Pubitemid 19101063)
43. Kukhanova M, Victorova L, Krayevsky A: Peptidyltransferase center of ribosomes. On the mechanism of action of alkaloid lycorine. FEBS Lett 1983;160:129-133. (Pubitemid 13048731)
44. Arcaro A, Wymann MP: Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: The role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J 1993;296(Pt 2):297-301. (Pubitemid 23350826)
45. Duncan GG: Quinacrine hydrochloride (atabrine) as a malaria suppressive agent. Air Surg Bull 1945;2:413.
46. O'Farrell AM, Abrams TJ, Yuen HA, et al.: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-3605. (Pubitemid 36857948)